Attached files

file filename
EX-31.2 - EX-31.2 - Aerovate Therapeutics, Inc.avte-20210630xex31d2.htm
EX-31.1 - EX-31.1 - Aerovate Therapeutics, Inc.avte-20210630xex31d1.htm
10-Q - FORM 10-Q - Aerovate Therapeutics, Inc.avte-20210630x10q.htm

Exhibit 32.1

CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Aerovate Therapeutics, Inc. (the “Company”) for the quarter ended June 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certify, pursuant to 18 U.S.C. Section 1350, that, to the best of their knowledge:

(1)

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Timothy P. Noyes

Timothy P. Noyes

Chief Executive Officer

(Principal Executive Officer)

Dated: August 16, 2021

/s/ George A. Eldridge

George A. Eldridge

Chief Financial Officer

(Principal Financial and Accounting Officer)

Dated: August 16, 2021